Deutsch English Français

Contact

EP2706983

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2706983

EP2706983 - NOVEL PHARMACEUTICAL FORMULATION [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 16.10.2015 Database last updated on 17.09.2024
Most recent event Tooltip	16.10.2015	Application deemed to be withdrawn	published on 18.11.2015 [2015/47]
Applicant(s)	For all designated states Vockner, Helmut Jodlfeld 4/4 6370 Kitzbühel / AT
	[2014/12]
Inventor(s)	01 / see applicant ...
	[2014/12]
Representative(s)	Loidl, Manuela Bettina, et al REDL Life Science Patent Attorneys Donau-City-Strasse 11 1220 Wien / AT
	[N/P]
Former [2014/12]	Loidl, Manuela Bettina, et al REDL Life Science Patent Attorneys Donau-City-Strasse 1 1220 Wien / AT
Application number, filing date	12726753.2	11.05.2012
	WO2012EP58738
Priority number, date	EP20110165857	12.05.2011 Original published format: EP 11165857
	[2014/12]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2012152910
	Date:	15.11.2012
	Language:	EN
	[2012/46]
	Type:	A1 Application with search report
	No.:	EP2706983
	Date:	19.03.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 15.11.2012 takes the place of the publication of the European patent application.
	[2014/12]
Search report(s)	International search report - published on:	EP	15.11.2012
Classification	IPC:	A61K9/00, A61K9/06, A61K9/08, A61K9/14, A61K31/155, A61K31/593, A61P17/02	[2014/12]
	CPC:	A61K9/006 (EP,US); A61K31/353 (US); A61K31/155 (EP,US); A61K31/593 (EP,US); A61K31/722 (EP,US); A61K45/06 (EP,US); (+) A61K9/0063 (EP,US); A61K9/06 (EP,US); A61P17/02 (EP) (-)
	C-Set:	A61K31/593, A61K2300/00 (US,EP); A61K31/722, A61K2300/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/12]
Extension states	BA	12.11.2013
	ME	12.11.2013
Title	German:	NEUE PHARMAZEUTISCHE FORMULIERUNG	[2014/12]
	English:	NOVEL PHARMACEUTICAL FORMULATION	[2014/12]
	French:	NOUVELLE FORMULATION PHARMACEUTIQUE	[2014/12]
Entry into regional phase	12.11.2013	National basic fee paid
	12.11.2013	Designation fee(s) paid
	12.11.2013	Examination fee paid
Examination procedure	08.03.2013	Request for preliminary examination filed International Preliminary Examining Authority: EP
	12.11.2013	Examination requested [2014/12]
	13.01.2015	Communication of intention to grant the patent
	27.05.2015	Application deemed to be withdrawn, date of legal effect [2015/47]
	30.06.2015	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2015/47]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.01.2015
Fees paid	Renewal fee
	26.05.2014	Renewal fee patent year 03
	Penalty fee
	Additional fee for renewal fee
	31.05.2015	04 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]CN1197643 (XIE RUIGANG [CN]) [X] 5,6,10-16 * the whole document *;
		[X]KR100930326B (UNIV KOREA RES & BUS FOUND [KR]) [X] 1,3,4,7,10,12,14 * pages 9,18 *;
		[XP]WO2011121062 (VOCKNER HELMUT [AT]) [XP] 5-8,10-17 * claims 1,3,12,18,19,20 *;
		[A] - COHEN R E ET AL, "Effect of vitamin E gel, placebo gel and chlorhexidine on periodontal disease", CLINICAL PREVENTIVE DENTISTRY UNITED STATES 1991 SEP-OCT,, (19910901), vol. 13, no. 5, ISSN 0163-9633, pages 20 - 24, XP009152624 [A] 5-17 * the whole document *
		[A] - KOIDE S S, "Chitin-chitosan: properties, benefits and risks", NUTRITION RESEARCH, ELSEVIER INC, XX, (19980601), vol. 18, no. 6, ISSN 0271-5317, pages 1091 - 1101, XP009161185 [A] 1-4,7,12-16 * page 1097 - page 1098 * DOI: http://dx.doi.org/10.1016/S0271-5317(98)00091-8
		[A] - RAMESH K V ET AL, "A new role for vitamin D: Cholecalciferol prmotes dermal wound strenght and re-epithelization", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH, IN, (19930901), vol. 31, ISSN 0019-5189, pages 778 - 779, XP002992050 [A] 14,15 * the whole document *
	by applicant	US2004122105
		JP2004210675
		JP2007084471
		WO2008073174
		- RUBIN, R.R; STADDON, J.M., ANNU REV NEUROSCI., (1999), vol. 22, pages 11 - 28
		- STADDON JM; RUBIN LL., CURR OPIN NEUROBIOL., (199610), vol. 6, no. 5, pages 622 - 7
		- GALLAGHER, K., J CLIN INVEST., (20070501), vol. 117, no. 5, pages 1249 - 1259
		- LLAVANERAS A. ET AL., J. PERIODONTOL., (2001), vol. 72, no. 8, pages 1069 - 1077
		- GREENWELL H.; BISSADA, N., DRUG, (2002), vol. 62, no. 18, pages 2681 - 2687
		- NOROWSKI P.; BAUMGARDNER J., J. BIOMED. MAT. RES., PAST B: APPLIED BIOMATERIALS, (2009), vol. 88, no. 2, pages 530 - 543
		- BADRAN Z. ET AL., ORAL HEALTH & PREVENTIVE DENTISTRY, (2009), vol. 7, no. 1, pages 3 - 12
		- RAMESH K.V. ET AL., INDIAN J. OF EXP. BIOLOGY, (1993), vol. 31, pages 778 - 779
		- COHEN R.E. ET AL., CLINICAL PREVENTIVE DENTISTRY, (1991), vol. 13, no. 5, pages 20 - 24
		- YOON, K, JOURNAL OF BIOLOGICAL CHEMISTRY, (2003), vol. 278, pages 15319 - 15325
		- HAUSLADEN, PRIVALLE ET AL., NAT. STRUCT. BIOL., (1996), vol. 5, pages 247 - 249
		- STAMLER; HAUSLADEN, CELL, (1998), vol. 86, pages 719 - 729
		- KSANDER BR, J IMMUNOL., (19901001), vol. 145, no. 7, pages 2057 - 63
		- KUBO TAKEKAZU, THE JOURNAL OF IMMUNOLOGY, (2004), vol. 173, pages 7249 - 7258
		- CHAPUY MC, OSTEOPOROS. INT., (200203), vol. 13, no. 3, pages 257 - 64
		- PEPPER C, BLOOD, (20030401), vol. 101, no. 7, pages 2454 - 60
		- PENNA G, J IMMUNOL, (2000), vol. 164, pages 2405 - 11
		- BARRAT F J, J EXP MED, (2002), vol. 195, pages 603 - 16
		- GRIFFIN MD, J STEROID BIOCHEM MOL BIOL, (2004), vol. 89-90, pages 443 - 8
		- XING N, BIOCHEM BIOPHYS RES COMMUN., (2002), vol. 297, pages 645 - 52
		- ULEVITCH RJ, NAT REV IMMUNOL, (2004), vol. 4, pages 512 - 520
		- MEDZHITOV R, N ENGL J MED, (2000), vol. 343, pages 338 - 344
		- HAJISHENGALLIS G, IMMUNOL INVEST, (2004), vol. 33, pages 157 - 172
		- GIBSON FC 3RD, CIRCULATION, (2004), vol. 109, pages 2801 - 2806
		- MUTHUKURU M, INFECT IMMUN, (2005), vol. 73, pages 687 - 694
		- BAINBRIDGE BW, ACTA ODONTOLSCAND, (2001), vol. 59, pages 131 - 138
		- CALIXTO JB, PLANTA MED, (2003), vol. 69, pages 973 - 983
		- HAROKOPAKIS E, J PERIODONTOL, (2006), vol. 2, pages 271 - 279
		- GREENAWAY W, A REPORT OF WORK AT OXFORD, (1990), pages 117 - 118
		- XING X, THE FOOD INDUSTRY, (2008), page 01
		- SOCRANSKY, J CLIN PERIODONTOL, (1998), vol. 25, pages 134 - 44
		CN19971003254

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p